{"id":"arm-a-abc-3tc-nnrti","safety":{"commonSideEffects":[{"rate":"5-8","effect":"Hypersensitivity reaction (abacavir)"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"15-20","effect":"Rash (NNRTI-related)"},{"rate":"10-15","effect":"Headache"},{"rate":"2-5","effect":"Hepatotoxicity"},{"rate":"<1","effect":"Lactic acidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABC (abacavir) and 3TC (lamivudine) are nucleoside reverse transcriptase inhibitors that compete with natural nucleotides and cause chain termination during viral DNA synthesis. The NNRTI component binds directly to reverse transcriptase and blocks its catalytic activity. Together, these three agents suppress HIV replication through complementary mechanisms targeting the same enzyme.","oneSentence":"This combination inhibits HIV reverse transcriptase through two nucleoside analogs (ABC and 3TC) and one non-nucleoside reverse transcriptase inhibitor (NNRTI), blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:10.879Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT02105987","phase":"PHASE3","title":"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04","conditions":"Infection, Human Immunodeficiency Virus","enrollment":555},{"nctId":"NCT02028676","phase":"PHASE4","title":"Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"2007-03","conditions":"Human Immunodeficiency Virus","enrollment":1206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABC: abacavir: Ziagen","3TC: lamivudine: Epivir","ABC+3TC co-formulated: Kivexa","NVP: nevirapine, Viramune","EFV: efavirenz, Sustiva"],"phase":"marketed","status":"active","brandName":"Arm A: ABC+3TC+NNRTI","genericName":"Arm A: ABC+3TC+NNRTI","companyName":"Medical Research Council","companyId":"medical-research-council","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV reverse transcriptase through two nucleoside analogs (ABC and 3TC) and one non-nucleoside reverse transcriptase inhibitor (NNRTI), blocking viral replication. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}